Proactive Research analyst Emma Ulker gives her view on the work MaxCyte Inc's (LON:MXCT) doing in the area of cell and gene therapy.
MXCT has more than 80 licensed programmes including more than 45 licensed for clinical use.
They've announced seven clinical/commercial partnership deals with leading names in the field of cell and gene therapy.
Ulker adds that the field is experiencing a huge step up in investment - rising by more than 77% year-on-year in 2018.